All companies
Visit website
VISIBLE GENOMICS
OperatingVisible Genomics, Inc.
Healthcare · Technology · Founded 2024
Preventing vision loss with a simple genetic test
Post-money valuation ⓘ
$26.4M
As of Nov 2024 · from Visible Genomics Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$0
Across 1 round since 2024
Latest share price
$9.48
Visible Genomics Common Stock 1 offering price
Financials
FY2022–FY2023 · from SEC filings · hover any figure for its source$33K
−$691K
2022
$32K
−$601K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
Income statement
Revenue
$33,360
$31,768
Cost of goods sold
$25,613
$26,490
Gross margin
23%
17%
Net income
-$691,435
-$600,827
Taxes paid
$0
$0
Balance sheet
Cash
$8,973
$3,808
Accounts receivable
$1,600
$2,300
Total assets
$16,821
$12,651
Short-term debt
$1,457,387
$2,004,044
Long-term debt
$0
$0
Total liabilities
$1,457,387
$2,004,044
Other
Headcount
—
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$26.4M
post-money
Visible Genomics Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $1.2MInvestors 6Post-money $26.4M
Reg CF annual-report compliance
Delinquent
Filed 0 of 2 annual reports (FY2024–FY2025)
Missing: 2024, 2025
6 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001779991Share price $9.48
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.